Table 1. Relative and absolute neutrophil counts and expression levels of surface markers on neutrophils in: A. healthy controls vs CLL, B. non-active CLL vs active CLL, C. untreated CLL vs treated CLL, D. mutated IGHV gene status vs unmutated IGHV gene status.
| Marker | Mean (95% CI) | FC# | P | |
|---|---|---|---|---|
| A | Healthy controls | CLL | ||
| CD64 (%) | 6.89 (3.73-10.0) | 26.3 (19.2-33.5) | 4.65 | 3.20 × 10-6 |
| CD54 (%)* | 16.2 (11.5-20.9) | 32.8 (24.6-41.0) | 1.92 | 2.93 × 10-3 |
| CD62L (%) | 98.3 (97.3-99.3) | 90.3 (86.3-94.3) | 0.98 | 4.47 × 10-5 |
| CD11b (%) | 96.5 (93.8-99.3) | 90.5 (85.3-95.7) | 0.99 | 0.07 |
| CD64 (MFI) | 58.8 (51.4-66.3) | 60.3 (51.8-68.8) | 0.89 | 0.71 |
| CD54 (MFI)* | 16.4 (15.9-17.0) | 20.1 (18.0-22.1) | 1.19 | 4.92 × 10-7 |
| CD62L (MFI) | 423 (334-512) | 302 (246-358) | 0.87 | 0.03 |
| CD11b (MFI) | 120 (103-138) | 148 (125-171) | 1.28 | 0.14 |
| Neutrophils (%) | 58.4 (56.2-60.7) | 16.9 (13.0-20.8) | 0.23 | 4.04 × 10−15 |
| Lymphocytes (%) | 28.8 (26.9-30.8) | 75.2 (70.7-79.6) | 2.73 | 3.91 × 10−15 |
| ANC (x109/L) | 4.82 (4.09-5.55) | 4.19 (3.62-4.75) | 0.76 | 0.10 |
| CD64+ ANC (x109/L) | 0.40 (0.08-0.71) | 1.06 (0.68-1.44) | 3.12 | 4.27 × 10−3 |
| CD54+ ANC (x109/L) | 0.59 (0.33-0.85) | 1.25 (0.90-1.60) | 2.56 | 4.14 × 10−3 |
| CD62L+ ANC (x109/L) | 4.79 (4.07-5.51) | 3.82 (3.29-4.35) | 0.73 | 0.03 |
| CD11b+ ANC (x109/L) | 4.81 (4.08-5.54) | 3.87 (3.28-4.47) | 0.74 | 0.04 |
| B | CLL non-active | CLL active | ||
| CD64 (%) | 15.7 (8.68-22.8) | 40.0 (27.8-52.1) | 4.91 | 3.01 × 10-3 |
| CD54 (%)* | 27.9 (17.7-38.2) | 38.5 (24.8-52.2) | 1.54 | 0.21 |
| CD62L (%) | 93.1 (88.2-98.1) | 88.3 (81.9-94.7) | 0.94 | 8.11 × 10-3 |
| CD11b (%) | 91.4 (84.2-98.6) | 90.5 (82.4-98.6) | 0.99 | 0.86 |
| CD64 (MFI) | 50.5 (43.4-57.6) | 69.9 (53.7-86.1) | 1.26 | 6.09 × 10-3 |
| CD54 (MFI)* | 17.9 (17.0-18.9) | 22.6 (18.3-26.8) | 1.06 | 2.93 × 10−3 |
| CD62L (MFI) | 363 (281-445) | 237 (165-310) | 0.51 | 0.03 |
| CD11b (MFI) | 145 (111-179) | 146 (114-178) | 1.02 | 0.70 |
| Neutrophils (%) | 23.4 (17.7-29.1) | 8.83 (5.07-12.6) | 0.32 | 6.26 × 10−5 |
| Lymphocytes (%) | 68.9 (62.4-75.5) | 82.7 (77.6-87.8) | 1.20 | 1.38 × 10−3 |
| CLL cells (%) | 60.3 (49.0-71.6) | 80.5 (72.0-89.0) | 1.23 | 2.67 × 10−3 |
| ANC (x109/L) | 4.42 (3.69-5.14) | 3.94 (2.97-4.92) | 0.82 | 0.25 |
| CD64+ ANC (x109/L) | 0.65 (0.33-0.97) | 1.59 (0.86-2.33) | 3.45 | 9.52 × 10−3 |
| CD54+ ANC (x109/L) | 1.17 (0.65-1.69) | 1.34 (0.83-1.85) | 1.33 | 0.36 |
| CD62L+ ANC (x109/L) | 4.07 (3.39-4.74) | 3.60 (2.70-4.49) | 0.87 | 0.24 |
| CD11b+ ANC (x109/L) | 4.12 (3.33-4.91) | 3.65 (2.68-4.63) | 0.78 | 0.38 |
| C | CLL untreated | CLL treated | ||
| CD64 (%) | 16.5 (9.12-23.9) | 35.5 (24.1-46.9) | 3.52 | 0.02 |
| CD54 (%)* | 23.3 (14.0-32.5) | 42.8 (29.9-55.8) | 2.07 | 0.01 |
| CD62L (%) | 93.0 (88.3-97.6) | 87.8 (81.2-94.4) | 0.98 | 0.18 |
| CD11b (%) | 94.6 (90.3-98.9) | 86.6 (77.3-95.9) | 0.99 | 0.17 |
| CD64 (MFI) | 45.6 (40.5-50.8) | 73.8 (59.5-88.1) | 1.58 | 3.51 × 10−5 |
| CD54 (MFI)* | 18.6 (17.6-19.5) | 21.7 (17.4-25.9) | 1.03 | 0.22 |
| CD62L (MFI) | 338 (243-433) | 269 (203-336) | 0.91 | 0.40 |
| CD11b (MFI) | 156 (118-193) | 140 (111-170) | 0.82 | 0.37 |
| Neutrophils (%) | 18.0 (12.7-23.3) | 15.9 (9.81-22.0) | 0.81 | 0.29 |
| Lymphocytes (%) | 76.6 (71.0-82.2) | 73.8 (66.5-81.0) | 0.97 | 0.80 |
| CLL cells (%) | 69.0 (59.5-78.6) | 69.5 (57.4-81.6) | 1.13 | 0.53 |
| ANC (x109/L) | 5.01 (4.14-5.87) | 3.42 (2.76-4.09) | 0.71 | 3.95 × 10−3 |
| CD64+ ANC (x109/L) | 0.94 (0.29-1.59) | 1.18 (0.73-1.63) | 2.35 | 0.15 |
| CD54+ ANC (x109/L) | 1.09 (0.54-1.64) | 1.41 (0.94-1.89) | 1.82 | 7.90 × 10−2 |
| CD62L+ ANC (x109/L) | 4.56 (3.82-5.31) | 3.13 (2.44-3.82) | 0.65 | 2.51 × 10−3 |
| CD11b+ ANC (x109/L) | 4.76 (3.90-5.62) | 3.05 (2.31-3.78) | 0.64 | 5.72 × 10−3 |
| D |
CLL IGHV mutated status |
CLL IGHV unmutated status | ||
| CD64 (%) | 17.2 (9.30-25.0) | 32.0 (19.8-44.1) | 1.74 | 0.23 |
| CD54 (%)* | 28.8 (17.5-40.1) | 38.3 (23.5-53.0) | 1.03 | 0.37 |
| CD62L (%) | 93.5 (87.5-99.5) | 87.4 (81.1-93.7) | 0.96 | 9.89 × 10-4 |
| CD11b (%) | 93.2 (86.0-100) | 88.8 (81.1-96.5) | 0.98 | 0.16 |
| CD64 (MFI) | 55.0 (43.8-66.1) | 66.2 (51.1-81.4) | 1.16 | 0.12 |
| CD54 (MFI)* | 18.5 (17.5-19.4) | 21.7 (16.9-26.5) | 1.03 | 0.27 |
| CD62L (MFI) | 389 (283-494) | 235 (173-296) | 0.67 | 0.02 |
| CD11b (MFI) | 148 (121-175) | 152 (109-195) | 0.79 | 0.62 |
| Neutrophils (%) | 21.1(14.7-27.4) | 13.5 (8.34-18.7) | 0.58 | 0.04 |
| Lymphocytes (%) | 72.8 (64.9-80.7) | 76.5 (70.7-82.4) | 1.09 | 0.52 |
| CLL cells (%) | 65.0 (52.8-77.3) | 71.3 (59.8-82.88) | 1.17 | 0.25 |
| ANC (x109/L) | 3.95 (3.29-4.61) | 4.42 (3.42-5.41) | 1.07 | 0.76 |
| CD64+ ANC (x109/L) | 0.65 (0.27-1.04) | 1.44 (0.74-2.15) | 2.65 | 0.12 |
| CD54+ ANC (x109/L) | 1.12 (0.58-1.67) | 1.47 (0.84-2.09) | 1.56 | 0.18 |
| CD62L+ ANC (x109/L) | 3.72 (3.02-4.41) | 3.91 (3.02-4.76) | 0.96 | 0.91 |
| CD11b+ ANC (x109/L) | 3.72 (3.00-4.44) | 4.01 (2.99-5.03) | 1.04 | 0.78 |
ANC: Absolute neutrophil count. The normal range for the ANC = 1.5 to 8.0x109/L.
#FC (Fold Change) between group medians
*CD54 available in 39 patients and 34 controls